Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Merrimack receives FDA orphan drug status for MM-398 to treat pancreatic cancer

Merrimack receives FDA orphan drug status for MM-398 to treat pancreatic cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Merrimack, PharmaEngine collaborate to develop and commercialize PEP02 in Asia and Europe

Merrimack, PharmaEngine collaborate to develop and commercialize PEP02 in Asia and Europe

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Champions enters exclusive license agreement with BCCA for Irinophore C

Champions enters exclusive license agreement with BCCA for Irinophore C

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck submits Erbitux indication extension to EMA for NSCLC treatment